← Back to headlines
RBC Trims Price Targets for ACADIA, Galapagos
RBC Capital Markets has slightly trimmed its price target for ACADIA Pharmaceuticals, citing seasonal biotech headwinds. The firm also cut its price target for Galapagos NV to $28, while maintaining a Sector Perform rating ahead of its Q1 earnings.
24 Apr, 13:44 — 24 Apr, 13:44
Sources
Showing 1 of 1 sources
